← FDA DRUG APPROVALS

FDA ANDA · ANDA211625

SUCCINYLCHOLINE CHLORIDE

Sponsor: NIVAGEN PHARMS INC

APPLICATION
ANDA211625
TYPE
ANDA
ORIGINAL APPROVAL
2020-05-19
LATEST ACTION
2023-04-07
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

SUCCINYLCHOLINE CHLORIDEPrescription
SUCCINYLCHOLINE CHLORIDE 20MG/ML · INJECTABLE · INJECTION

Approval history

2023-04-07Labeling · Supplement 2 · standardAP
2021-10-26Labeling · Supplement 1 · standardAP
2020-05-19UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →